Low Mutation Rate in iPSCs

The mutation rate in induced pluripotent stem cells is 10 times lower than in somatic cells, scientists show.

Written byCatherine Offord
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Human embryonic stem cellsWIKIMEDIA, NISSIM BENVENISTYResearchers in the U.K. have developed a technique to track and compare the mutations occurring in lab-grown somatic cells and induced pluripotent stem cells (iPSCs), according to a study published last week (April 7) in PLOS Genetics. Their findings reveal a lower mutation rate in iPSCs compared to lab-grown somatic cells, plus a low risk of generating cancer-related mutations while creating the stem cells, providing further support for the safety of using iPSCs in regenerative medicine.

“Until now, the question of whether generating iPS cells and growing them in cell culture creates mutations has not been addressed in detail,” study coauthor Allan Bradley of the Wellcome Trust Sanger Institute in the U.K. said in a statement. “If human cells are really to be reprogrammed on a large scale for use in regenerative medicine then understanding the mutations the donor cells carry will be a crucial step. We now have the tools to do this.”

Previous work has shown that iPSCs exhibit relatively few mutational differences from their parent cells, but this study marks the first time that researchers have tracked the accumulation of mutations in iPSCs and somatic cells as they grow in the lab. Using cells donated by a healthy, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies